Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France.
APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence Des Mycobactéries Et de La Résistance Des Mycobactéries Aux Antituberculeux, Paris, France.
Sci Rep. 2021 Oct 25;11(1):20964. doi: 10.1038/s41598-021-00243-4.
Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.
多中心、回顾性队列研究，采用多变量 Cox 比例风险模型和生存时间逆概率加权法，评估不同治疗方法对意大利皮亚琴扎省两家医院收治的确诊 COVID-19 患者生存的影响。使用托珠单抗和高剂量低分子量肝素，但不使用抗病毒药物（单独或联合使用）、阿奇霉素和任何皮质类固醇，与较低的死亡率独立相关。我们的研究结果支持进一步评估高剂量低分子量肝素和托珠单抗作为 COVID-19 治疗药物的临床疗效。
